Rapid Diagnostek

company

About

Rapid Diagnostek develops biosensor-based diagnostic tests for the detection of proteins, bacteria and viruses contained in liquid samples.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Industries
Agriculture,Biotechnology,Genetics,Health Diagnostics,Life Science
Founded date
Jan 1, 1986
Number Of Employee
11 - 50
Operating Status
Active

Rapid Diagnostek formerly Intellignostics, has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing. Its technology offers remarkably faster and less expensive results than existing methods. Current diagnostic tests can take hours to days from the time a sample is taken to delivery of results.

Rapid Diagnostek's IntelliProbe Immunosensor (IPI) platform can deliver results at the point of sampling in under 60 seconds. The sensor has performed as intended in the laboratory and the company is now developing a fully functioning device and initial assays to aggressively move towards commercialization.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Rapid Diagnostek has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 1, 2019 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 1, 2019 Series Unknown 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Rapid Diagnostek is funded by 1 investors. NEW Capital Fund are the most recent investors.
Investor Name Lead Investor Funding Round
NEW Capital Fund Series Unknown